1. Medtech Insight
  2. >>Archive

Pulmonology: The Next Interventional Cardiology

Pulmonologists, a group of device-friendly physicians without many tools at their disposal, treat large diseases with unmet needs like emphysema, asthma, and lung cancer. They thus represent an attractive, untapped market for medical device companies. Many companies targeting emphysema have been formed by executives from the interventional cardiology industry and aim to follow the tried and true path of that industry, of introducing new minimally-invasive versions of open surgical predicate procedures. Others are following the tougher route of working in diseases like asthma, for which no device predicates exist. Companies hope to offer high volume procedures that will grow interventional pulmonology from a niche specialty treating end-stage cancer patients to a specialty that routinely performs millions of procedures on patients with non-malignant diseases that are currently poorly managed by drugs.

by Mary Stuart

In which medical specialty do physicians aggressively adopt new technologies, perform minimally-invasive versions of open surgical procedures with stents, brachytherapy, and lasers to remove lumen obstructions, and treat diseases that afflict millions of patients, one of which is the fourth major cause of death in the US? The answer is pulmonology, and the diseases are lung cancer, chronic obstructive pulmonary disease, and asthma. But this burgeoning sub-specialty bears a striking resemblance to interventional cardiology, a similarity that isn't lost on cardiovascular companies Boston Scientific Corp. , Guidant Corp. , and Johnson & Johnson , as well as many venture capital firms, all of which have made investments in pulmonology recently

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Faster Device Certification Among Keys To Unlocking Innovation In EU MedTech Sector

 
• By Amanda Maxwell

While MedTech Europe sharpens its focus on what the EU most urgently needs to advance the medtech market in four targeted measures, the European Commission has also unveiled four priorities for 2025.

GE HealthCare Warns Of $500M Tariff Hit In 2025, Eyes Recovery in 2026

 
• By Shubham Singh

GE HealthCare anticipates most of the $0.85 EPS tariff impact will play out in the second half of 2025. Jay Saccaro, vice president and CFO, said the tariff-related burden is minimal in Q1 at about $10 million, rising to nearly $100 million in Q2 and then spiking to around $200 million each in Q3 and Q4.

Peerbridge Bets On At-Home Heart Monitoring With Rechargeable, Longer-Lasting ECG Patch

 
• By Marion Webb

Peerbridge Health is preparing to submit its next-generation ECG patch, CorMDx, for US FDA clearance this quarter, with plans to launch in the second half of 2025. The rechargeable device is designed for continuous, real-time heart monitoring from the hospital to home, aiming to detect early signs of heart failure and reduce emergency room visits.